Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) dropped 3.1% on Friday . The stock traded as low as $3.11 and last traded at $3.15, with a volume of 183,709 shares traded. The stock had previously closed at $3.25.

ANTH has been the topic of several research analyst reports. HC Wainwright initiated coverage on Anthera Pharmaceuticals in a research report on Friday, July 8th. They set a “buy” rating and a $10.00 target price on the stock. Jefferies Group restated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 9th. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Thursday, May 12th. Finally, FBR & Co restated a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Anthera Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $9.58.

The company’s market cap is $129.93 million. The firm’s 50-day moving average is $3.19 and its 200 day moving average is $3.41.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. Analysts predict that Anthera Pharmaceuticals Inc. will post ($1.26) earnings per share for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.